UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 645

Sortiert nach

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

Critical reviews in oncology/hematology, 2017-09, Vol.117, p.38-47

2017

Volltextzugriff (PDF)

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2002-11, Vol.20 (21), p.4285-4291

2002

Volltextzugriff (PDF)

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

ESMO open, 2022-04, Vol.7 (2), p.100406-100406, Article 100406

2022

Volltextzugriff (PDF)

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial

Annals of oncology, 2016-11, Vol.27 (11), p.2074-2081

2016

Volltextzugriff (PDF)

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

Critical reviews in oncology/hematology, 2018-10, Vol.130, p.1-12

2018

Volltextzugriff (PDF)

The role of Aurora-A inhibitors in cancer therapy

Annals of oncology, 2007-06, Vol.18 (suppl-6), p.vi47-vi52

2007

Volltextzugriff (PDF)

1893 The role of Androgen Receptor, E-cadherin and Ki67 as novel prognostic markers in Triple Negative Breast Cancer (TNBC)

European journal of cancer (1990), 2015-09, Vol.51, p.S297-S297

2015

Volltextzugriff (PDF)

Photography as a therapeutic tool to re-elaborate “cancer” experience

Annals of oncology, 2017-10, Vol.28, p.vi87-vi88

2017

Volltextzugriff (PDF)

Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

Journal of clinical oncology, 1999-11, Vol.17 (11), p.3522-3530

1999

Volltextzugriff (PDF)

Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study)

Annals of oncology, 2018-10, Vol.29, p.viii102-viii102

2018

Volltextzugriff (PDF)

Efficacy and safety of the combination of pertuzumab (P) plus trastuzumab (T) plus docetaxel (D) for HER-2 positive metastatic breast cancer (MBC) in pretreated patients (pts) with trastuzumab in the neo/adjuvant setting: a retrospective real-life study

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi41

2017

Volltextzugriff (PDF)

Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung

Annals of oncology, 2017-10, Vol.28, p.vi78-vi78

2017

Volltextzugriff (PDF)

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

Annals of oncology, 2017-10, Vol.28, p.vi61-vi61

2017

Volltextzugriff (PDF)

Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study

Annals of oncology, 2019-07, Vol.30, p.iv115-iv115

2019

Volltextzugriff (PDF)

Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study

Annals of oncology, 2017-10, Vol.28 Suppl 6, p.vi40

2017

Volltextzugriff (PDF)

Photochromic Switches Incorporated in Bridging Ligands: A New Tool to Modulate Energy-Transfer Processes

Advanced functional materials, 2006-01, Vol.16 (2), p.195-208

2006

Volltextzugriff (PDF)

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer

British journal of cancer, 2004-06, Vol.90 (12), p.2288-2296

2004

Volltextzugriff (PDF)

Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas

Anticancer research, 2011-04, Vol.31 (4), p.1315-1320

2011

Volltextzugriff (PDF)

Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients

Annals of oncology, 2007-06, Vol.18 (suppl-6), p.vi53-vi57

2007

Volltextzugriff (PDF)

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

Breast cancer research and treatment, 2013-08, Vol.141 (1), p.101-110

2013

Volltextzugriff (PDF)

Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]

ESMO open, 2022-04, Vol.7 (2), p.100471-100471, Article 100471

2022

Volltextzugriff (PDF)

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

Journal of clinical oncology, 1997-01, Vol.15 (1), p.297-303

1997

Volltextzugriff (PDF)

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent metastatic breast cancer: a multicentre phase II study

British journal of cancer, 2008-06, Vol.98 (12), p.1916-1921

2008

Volltextzugriff (PDF)

47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?

Lung cancer (Amsterdam, Netherlands), 2013-05, Vol.80, p.S20-S21

2013

Volltextzugriff (PDF)

1 – 25 von 645

Suche als RSS-Feed

Aktive Filter

PublikationsformBücher

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(566)
Mit Volltextzugriff
(556)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(331)
Life Sciences & Biomedicine
(244)
Humans
(206)
Female
(142)
Male
(118)
Biological And Medical Sciences
(95)
Middle Aged
(89)
Adult
(88)
Aged
(88)
Medical Sciences
(79)
Oncology
(73)
Physical Sciences
(71)
Animals
(45)
Physics
(44)
Pharmacology. Drug Treatments
(34)
Chemistry
(32)
Tumors
(29)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(28)
Technology
(28)
Aged, 80 And Over
(27)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial

The changing scenario of 1st line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy

The role of Aurora-A inhibitors in cancer therapy

1893 The role of Androgen Receptor, E-cadherin and Ki67 as novel prognostic markers in Triple Negative Breast Cancer (TNBC)

Photography as a therapeutic tool to re-elaborate “cancer” experience

Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project

Nab-paclitaxel (nab-P) in metastatic breast cancer (MBC) in elderly patients: A real life setting (NEREIDE study)

Efficacy and safety of the combination of pertuzumab (P) plus trastuzumab (T) plus docetaxel (D) for HER-2 positive metastatic breast cancer (MBC) in pretreated patients (pts) with trastuzumab in the neo/adjuvant setting: a retrospective real-life study

Retrospective analysis of the therapeutic efficacy of platinum/etoposide schedules in the treatment of advanced poor differentiated neuroendocrine carcinomas of the lung

Baseline absolute neutrophil count (ANC), derived neutrophil-to-lymphocyte ratio (dNLR) and platelet-to-lymphocyte ratio (PLR) and outcome in non small cell lung cancer (NSCLC) treated with nivolumab or docetaxel: a preliminary analysis

Health-related quality of life in RAS wild-type metastatic colorectal cancer patients treated with panitumumab plus FOLFOX followed by panitumumab or panitumumab plus 5-FU/LV maintenance: the secondary endpoint of the Valentino study

Safety and efficacy of the treatment with Nab-paclitaxel in mEtastatic bREast cancer In elDerly patiEnts: NEREIDE study

Photochromic Switches Incorporated in Bridging Ligands: A New Tool to Modulate Energy-Transfer Processes

Negative hyper-selection of RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients randomized to first-line FOLFOX plus panitumumab (Pan) followed by maintenance therapy with either 5FU/LV plus pan or single-agent pan: Translational analyses of the VALENTINO study

Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer

Prognostic impact of CD133 immunoexpression in node-negative invasive breast carcinomas

Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study

Erratum to ‘Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario’: [ESMO Open Volume 7, Issue 2, April 2022, 100406]

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent metastatic breast cancer: a multicentre phase II study

47P TREATMENT OPTIONS FOR SMALL CELL LUNG CANCER: DOES LANREOTIDE REPRESENT A NEW CHOICE?

Aktive Filter

Suchergebnisse filtern